Gilead Sciences, Inc (GILD34) Fair Value & Analysis
Healthcare · BR · Market cap R$839B
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 20 days ago
Share price +6.5% over the past month.
Price vs Fair Value (12 months)
12‑month range R$291.45 – R$394.84 · fair‑value band R$36.53 – R$66.24 · the R$337.47 price screens above the R$51.59 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Gilead Sciences, Inc (GILD34) currently trades at R$337.47, while our model-based Fair Value estimate is R$51.59 — implying the stock looks roughly 84.7% overvalued today. We read business quality at 73/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Gilead Sciences, Inc generated revenue of R$29.7B at a net margin of 31.0%. Revenue grew 4.4% year over year. It earns a return on equity of 43.4%. Net debt stands at R$17.4B. Fundamentals as of Jun 24, 2026
Our scenario range runs from R$36.53 (bear case) to R$66.24 (bull case); at R$337.47, the current price sits above that range. The share trades about 15% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -36% fair-value upside — at -85%, GILD34 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Gilead Sciences, Inc reported revenue of R$29.4B in FY2025 versus R$27.3B in FY2021, a compound +1.9%/yr. Reported net income was R$8.5B in FY2025, compounding +8.1%/yr from FY2021.
Is GILD34 fairly valued? → Check now
Recent news
- Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
- Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?
- Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access
- Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,131 | $447.74 | -60% |
| Johnson & Johnson, JNJ | C$29.84 | C$15.84 | -47% |
| AbbVie Inc 4AB | €196.25 | €89.57 | -54% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$72.90 | R$13.54 | -81% |
| Novartis AG NVSN | 2,601 MXN | 1,897 MXN | -27% |
| AstraZeneca PLC ZEG | €160.70 | €128.63 | -20% |
| Novo Nordisk A/S NOV | €43.13 | €39.51 | -8% |
| Amgen Inc AMGN | $345.60 | $219.60 | -36% |
| Pfizer Inc PFE | $26.04 | $13.31 | -49% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Gilead Sciences, Inc (GILD34) undervalued?
What is the fair value of GILD34?
What is the quality score of GILD34?
What is the revenue of Gilead Sciences, Inc (GILD34)?
What is the net profit margin of GILD34?
Does Gilead Sciences, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Gilead Sciences, Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.